

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



長春達興藥業股份有限公司

CHANGCHUN DA XING PHARMACEUTICAL COMPANY LIMITED*

(a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 8067)

ANNOUNCEMENT

The Board wishes to inform the shareholders of the Company that the announcements of the 2005 Interim Result, the 2005 Q3 Result and the 2005 Annual Result and the dispatch of the 2005 Interim Report, the 2005 Q3 Report and the 2005 Annual Report are delayed due to the process of compiling the PRC Police enquiry and investigation and in the process of Internal Enquiry. Such delays constitute breaches of Rules 18.03, 18.53 and 18.66 of the GEM Listing Rules.

Accordingly, the delay in the publication of the 2005 Interim Result, the 2005 Q3 Result and the 2005 Annual Result will cause delay of the announcement of the 2006 Q1 Result. Such delay constitute breaches of Rule 18.66 of the GEM Listing Rules.

The board will inform the shareholders of the Company as soon as practicable when the Company is able to announce the 2005 Interim Result, the 2005 Q3 Result, the 2005 Annual Result and the 2006 Q1 Result and dispatch of the 2005 Interim Result, the 2005 Q3 Result, the 2005 Annual Result and the 2006 Q1 Result.

Trading in shares of the Company was suspended effective from 28 July 2005 and remains suspended until further notice.

The board of directors (“the Board”) of Changchun Da Xing Pharmaceutical Company Limited (the “Company”) refers to the announcement of the Company dated 9 August 2005 in relation to the Company have detected certain irregularities in its accounting records (“Irregularities”) and the Board have commenced (“Internal Enquiry”) in conducting on the Irregularities. The police department of the Government of the People’s Republic of China (“PRC Police”) has made enquiry to the Company and commenced investigation on the Irregularities. The process of the Internal Enquiry and the process of investigation and enquiry make by the PRC Police are still under going. As a result, the Board wishes to announce that there will be delay of the announcement of the results of the Company for the six months ended 30 June 2005 (the “2005 Interim Result”), the nine months ended 30 September 2005 (the “2005

* For identification purposes only

Q3 Result”), the year ended 31 December 2005 (the “2005 Annual Result”) and dispatch of the corresponding interim report (the “2005 Interim Report”), third quarterly report (the “2005 Q3 Report”) and the annual report (the “2005 Annual Report”). Such delays constitute breaches of Rules 18.03, 18.53 and 18.66 of the Rules Governing the Listing of the Securities on the Growth Enterprise Market (the “GEM Listing Rules”) of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”).

Accordingly, the delay in the publication of the 2005 Interim Result, 2005 Q3 Result and the 2005 Annual Result will cause delay of the announcement of the results of the Company for the three months ended 31 March 2006 (“2006 Q1 Result”) and the dispatch of first quarterly report for the same period (the “2006 Q1 Report”). Such delay will constitute breaches of Rule 18.66 of the GEM Listing Rules.

The Board will inform the shareholders of the Company as soon as practicable when the Company is able to announce the 2005 Interim Result, the 2005 Q3 Result, the 2005 Annual Result and the 2006 Q1 Result and dispatch of the 2005 Interim Report, the 2005 Q3 Report, the 2005 Annual Report and the 2006 Q1 Report.

At the request of the Company, trading in the shares of the Company on the Stock Exchange was suspended with effect from 10:00 a.m. on 28 July 2005 and will remain suspended until further notice.

By order of the Board
Changchun Da Xing Pharmaceutical Company Limited
Qu Lian Qin
Chairman

Changchun, the PRC, 31 March, 2006

As at the date of this announcement the Board comprises five executive directors, being Qu Lian Qin, Yu Cheng Kun, Lu De Yi, Guo Bin and Zhang Dong Hai; a non-executive director, Dong Guo Zhi; and three independent non-executive directors, being Yang Shi Jie, Sun Xiao Bo and Zhang Zhong Sheng.

This announcement, for which the directors of Changchun Da Xing Pharmaceutical Company Limited (the “Directors”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to Changchun Da Xing Pharmaceutical Company Limited. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this announcement misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the GEM website at <http://www.hkgem.com> on the “Latest Company Announcements” page for at least 7 days from the date of its posting.